Related Experiment Video

Updated: May 11, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

What place for ▾racecadotril?

    Drug and Therapeutics Bulletin
    |May 10, 2013
    PubMed

    Insights

    Racecadotril (Hidrasec) offers symptomatic relief for acute diarrhoea by reducing intestinal fluid secretion. This enkephalinase inhibitor is a new treatment option for adults and children experiencing diarrhoea.

    Area of Science:

    • Pharmacology
    • Gastroenterology

    Background:

    • Diarrhoeal diseases cause 2 billion cases globally each year, leading to 1.5 million deaths in children under 5.
    • Dehydration is the most severe complication of diarrhoea.
    • In the UK, 10% of children under 5 present with gastroenteritis annually.

    Purpose of the Study:

    • To review the evidence for racecadotril (Hidrasec).
    • To determine the place of racecadotril in managing acute diarrhoea.

    Main Methods:

    • Review of existing evidence on racecadotril.
    • Analysis of its mechanism of action (enkephalinase inhibitor).

    Main Results:

    • Racecadotril is a novel antidiarrhoeal drug with an antisecretory mechanism.
    • It is licensed for symptomatic treatment of acute diarrhoea in adults, children, and infants over 3 months.

    Conclusions:

    • Racecadotril represents a new class of antidiarrhoeal medication.
    • It provides a valuable option for the symptomatic management of acute diarrhoea.

    More Related Videos

    Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

    Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

    Published on: April 4, 2022

    Related Concept Videos

    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    Antihypertensive Drugs: Vasodilators01:23

    Antihypertensive Drugs: Vasodilators

    Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    Antihypertensive Drugs: Thiazide-Class Diuretics01:15

    Antihypertensive Drugs: Thiazide-Class Diuretics

    Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...